JANX - Janux Therapeutics, Inc.
About Janux Therapeutics, Inc. (https://www.januxrx.com)
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| David Alan Campbell | President, Co-Founder, CEO & Director | 1960 | $1,047,200 USD |
| Thomas Diraimondo | Chief Scientific Officer | 1986 | $653,904 USD |
| William Y. Go | Chief Medical Officer | 1976 | $626,400 USD |
| Charles Winter | Chief Technical Officer | 1969 | $590,400 USD |
| Janeen Doyle | Chief Corporate & Business Development Officer | 1978 | $549,029 USD |
| James Pennington | General Counsel & Corporate Secretary | – | – |
| Maria Dobek | Vice President of Accounting | 1990 | – |
| Matt Whitmire | Vice President of Finance | – | – |